BioSpace News Archive

PD-1 Antagonist Antibody Under Clinical Development for Solid Tumors in Collaboration with GlaxoSmithKline (GSK) First AnaptysBio-Generated Antibody, of 8 Currently Under Clinical Development, to Obtain FDA Approval $20MM Milestone Payment Earned by AnaptysBio Upon FDA Approval; Additional $45MM and $165MM Milestones Due Upon Dostarlimab Regulatory and Commercial Milestones, Respectively AnaptysBio Due to Receive 8% to 25% Royalty on Global Net Sales

Lannett Company, Inc. (NYSE: LCI) today announced the closing of the $350 million aggregate principal amount of 7.750% senior secured notes due 2026 (the “Notes”) in a private placement

Vaxess Technologies, Inc., a biotechnology company developing vaccines and therapeutics delivered through a next-generation sustained-release intradermal microneedle patch, announced it was awarded a Commercialization Readiness Program (CRP) grant from the National Institute of Allergy and Infectious Diseases (NIAID grant number SB1AI164584), a part of the U.S. National Institutes of Health (NIH).

Denver-based healthtech leader Eon today announced that Dr. Scott Skibo has joined the company as Chief Medical Officer to further advance its mission to make patients healthier and healthcare affordable.

Thomas Scientific, the largest pure-play distributor of scientific products in the US, has officially entered into a supplier partnership with MicroGEM, a leading innovator of nucleic acid extraction products and techniques within laboratory workflows.

Cerner Corporation, a global healthcare technology company, announced that it has been named #57 among America’s top employers for diversity by Forbes, up 230 rankings from last year.

Qrons Inc., an innovative biotechnology company developing next generation treatments for unmet neuronal diseases, using tissue engineering, stem cells and machine learning synergic technologies is proud to report that the United States Patent and Trademark Office has issued U.S. Patent No. 10,954,315 to the Trustees of Dartmouth College which is directed to mechanically interlocked,molecules-based materials for 3-D printing.

The number of Americans aged 65 and older with Alzheimer’s disease (AD) is expected to more than double from 6.2 million today to 12.7 million by 2050.

Strategikon Pharma, a leader in digital business technology to accelerate planning, budgeting, and outsourcing for clinical trials, announced the closing of Series A financing.

CND Life Sciences, Inc., an innovative medical technology company pioneering the detection, visualization, and quantification of protein deposition in cutaneous nerve fibers, announced today its national collaboration with NuFactor®, a specialty infusion company and subsidiary of FFF Enterprises, Inc.,